-
公开(公告)号：US20130164295A1
公开(公告)日：2013-06-27
申请号：US13625417
申请日：2012-09-24
IPC分类号： C07K16/22 , A61K39/395 , A61K45/00 , C07K16/18
CPC分类号： C07K16/28 , A61K31/4745 , A61K31/7068 , A61K39/00 , A61K39/395 , A61K39/3955 , A61K45/00 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/22 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
-
公开(公告)号：US09376488B2
公开(公告)日：2016-06-28
申请号：US14476582
申请日：2014-09-03
IPC分类号： C07K16/22 , A61K39/395 , C07K16/18 , A61K45/00 , C07K16/28 , A61K45/06 , A61K31/4745 , A61K31/7068 , A61K39/00
CPC分类号： C07K16/28 , A61K31/4745 , A61K31/7068 , A61K39/00 , A61K39/395 , A61K39/3955 , A61K45/00 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/22 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
摘要翻译： 本发明涉及VEGF结合剂，DLL4结合剂，VEGF / DLL4双特异性结合剂，以及使用该药物治疗诸如癌症的疾病的方法。 本发明提供了特异性结合人VEGF的抗体，特异性结合人DLL4的抗体，以及特异性结合人VEGF和/或人类DLL4的双特异性抗体。 本发明还提供了使用这些药物来抑制肿瘤生长的方法。 还描述了治疗癌症的方法，其包括向具有肿瘤或癌症的患者施用治疗有效量的本发明的药剂或抗体。
-
公开(公告)号：US09168300B2
公开(公告)日：2015-10-27
申请号：US14212177
申请日：2014-03-14
IPC分类号： A61K39/395 , C07K14/71 , C07K16/28 , A61K39/00
CPC分类号： C07K16/32 , A61K39/39558 , A61K2039/505 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K2317/31 , C07K2317/35 , C07K2317/64 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer.
摘要翻译： 本发明涉及特异性结合人MET的结合剂，特异性结合WNT途径的一种或多种组分的结合剂，结合人MET和WNT途径的一种或多种组分的双特异性试剂，以及使用该试剂的方法 用于治疗诸如癌症的疾病。
-
公开(公告)号：US20170183406A1
公开(公告)日：2017-06-29
申请号：US15401543
申请日：2017-01-09
CPC分类号： C07K16/28 , A61K31/4745 , A61K31/7068 , A61K39/00 , A61K39/395 , A61K39/3955 , A61K45/00 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/22 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
-
公开(公告)号：US20210061903A1
公开(公告)日：2021-03-04
申请号：US16928452
申请日：2020-07-14
IPC分类号： C07K16/28 , A61K45/06 , A61K31/4745 , A61K31/7068 , A61K39/395 , C07K16/22 , A61K39/00 , A61K45/00 , C07K16/18 , C07K16/30
摘要： The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
-
公开(公告)号：US09574009B2
公开(公告)日：2017-02-21
申请号：US15163301
申请日：2016-05-24
CPC分类号： C07K16/28 , A61K31/4745 , A61K31/7068 , A61K39/00 , A61K39/395 , A61K39/3955 , A61K45/00 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/22 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
摘要翻译： 本发明涉及VEGF结合剂，DLL4结合剂，VEGF / DLL4双特异性结合剂，以及使用该药物治疗诸如癌症的疾病的方法。 本发明提供了特异性结合人VEGF的抗体，特异性结合人DLL4的抗体，以及特异性结合人VEGF和/或人类DLL4的双特异性抗体。 本发明还提供了使用这些药物来抑制肿瘤生长的方法。 还描述了治疗癌症的方法，其包括向具有肿瘤或癌症的患者施用治疗有效量的本发明的药剂或抗体。
-
公开(公告)号：US08858941B2
公开(公告)日：2014-10-14
申请号：US13625417
申请日：2012-09-24
IPC分类号： A61K39/395 , C12P21/08 , C07K16/00 , C07K16/22 , C07K16/28 , C07K16/18 , A61K45/00 , A61K39/00
CPC分类号： C07K16/28 , A61K31/4745 , A61K31/7068 , A61K39/00 , A61K39/395 , A61K39/3955 , A61K45/00 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/22 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
摘要翻译： 本发明涉及VEGF结合剂，DLL4结合剂，VEGF / DLL4双特异性结合剂，以及使用该药物治疗诸如癌症的疾病的方法。 本发明提供了特异性结合人VEGF的抗体，特异性结合人DLL4的抗体，以及特异性结合人VEGF和/或人类DLL4的双特异性抗体。 本发明还提供了使用这些药物来抑制肿瘤生长的方法。 还描述了治疗癌症的方法，其包括向具有肿瘤或癌症的患者施用治疗有效量的本发明的药剂或抗体。
-
公开(公告)号：US10730940B2
公开(公告)日：2020-08-04
申请号：US15847335
申请日：2017-12-19
IPC分类号： A61K39/395 , C07K16/22 , C07K16/28 , C07K16/46 , A61K45/06 , A61K31/4745 , A61K31/7068 , A61K39/00 , A61K45/00 , C07K16/18 , C07K16/30
摘要： The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
-
公开(公告)号：US09879084B2
公开(公告)日：2018-01-30
申请号：US15401543
申请日：2017-01-09
CPC分类号： C07K16/28 , A61K31/4745 , A61K31/7068 , A61K39/00 , A61K39/395 , A61K39/3955 , A61K45/00 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/22 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
-
公开(公告)号：US20160137744A1
公开(公告)日：2016-05-19
申请号：US14852916
申请日：2015-09-14
CPC分类号： C07K16/32 , A61K39/39558 , A61K2039/505 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K2317/31 , C07K2317/35 , C07K2317/64 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.03 秒)
